Categories AlphaGraphs, Earnings, Health Care

AngioDynamics (ANGO) Q3 earnings beat estimates as sales increase

AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported higher earnings for the third quarter of 2022 when the medical device maker’s net sales increased by 4%. The bottom line also exceeded Wall Street’s estimates.

AngioDynamics Q3 2022 earnings infographic

Earnings, adjusted for one-off items, increased to $0.03 per share in the most recent quarter from $0.02 per share in the same period of last year and came in above the market’s projection. On an unadjusted basis, it was a net loss of $4.9 million or $0.13 per share, compared to a loss of $3.5 million or $0.09 per share in the third quarter of 2021.

At $73.9 million, net sales were up 4% year-over-year. Analysts were looking for faster growth. Looking ahead, the management expects net sales to be in the range of $310 million to $315 million in the whole of fiscal 2022. It is estimated that the bottom line would range between a loss of $0.02 per share and earnings of $0.02 per share in the fiscal year.

“Even as we started to see benefits of our capacity enhancement initiatives, we saw our backlog increase during our third quarter, signaling continued strong customer demand. Since mid-February, we have seen steady improvement in procedure volumes and remain confident in both the long-term growth trajectory of our portfolio and the strategic transformation of the Company,” said Jim Clemmer, chief executive officer of AngioDynamics.


Read management/analysts’ comments on AngioDynamics’ Q3 2022 earnings


Shares of AngioDynamics traded higher early Thursday, after closing the previous session slightly above $21. The stock has lost about 26% since the beginning of the year.

Most Popular

Cost reduction has become a priority for FedEx (FDX) after a challenging quarter

Shares of FedEx Corporation (NYSE: FDX) were up 1% on Tuesday. The stock has dropped 44% year-to-date and 34% over the past 12 months. The company delivered mixed results for

Prime Medicine is the next big biotech to pursue IPO. Here’s all you need to know

After a soft start to the year, the IPO market has witnessed muted activity so far though a few big companies entered the stock market. On the heels of AIG

Stock Watch: Is Darden Restaurants a good buy after earnings?

After a prolonged slowdown, the restaurant industry is returning to normal patterns but macroeconomic uncertainties and high inflation are currently playing spoilsport for it. While the pandemic-related slump forced many

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top